Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/vucBYeM1P5 https://t.co/YqdqZWFhfd
Links:
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analy…
https://bit.ly/3MJUnUP
12-11-2023